πŸš€ Welcome to Amino Acid Designer!

Explore and learn through interactive simulation. Choose your learning level:

🧬

Amino Acid Designer

Beyond Nature's 20: Design Your Protein!

🎯 2024: The Golden Age of Protein Engineering
200+ designer amino acids β€’ 8 FDA-approved ADC drugs β€’ Nobel Prize Click Chemistry (2022)
200+
Non-Natural AAs
8+
FDA ADC Drugs
$15B+
Market Value
2022
Nobel Prize

🎯 Choose Your Depth

Beginner
Natural 20 basics!

πŸ€” What are Non-Natural Amino Acids?

Nature uses only 20 amino acids to build ALL proteins. But scientists have created 200+ new ones with superpowers! Add fluorine for PET imaging, click chemistry groups for precise drug attachment (Nobel Prize 2022), or D-amino acids that bacteria can't digest. FDA approved 8+ ADC cancer drugs using these in 2024!

Why revolutionary? Natural amino acids limit what proteins can do. Non-natural ones add: fluorescent tags for imaging, bioorthogonal chemistry (reactions that work only in living cells), protease resistance (drugs last longer), metal binding for catalysis.

πŸ’Š
Cancer ADC Drugs
8+ FDA-approved antibody-drug conjugates
πŸ“Έ
PET Imaging
Fluorine-18 labeled amino acids
πŸ”—
Click Chemistry
Nobel Prize 2022
πŸ›‘οΈ
Protease-Resistant
D-amino acids survive digestion
πŸ§ͺ
Bioplastics
Biodegradable and antimicrobial
βš™οΈ
Metalloenzymes
Designer amino acids with metal binding
🧬 Amino Acid Types
βš™οΈ Properties
Hydrophobicity 50%
Charge State Neutral
Side Chain Size Medium
Ser Serine - Polar, Uncharged
Classification
Polar Uncharged
Molecular Weight
105.09 Da
pI (Isoelectric)
5.68
Codon(s)
UCU, UCC, UCA, UCG

🧬 The Natural 20 Amino Acids

Hydrophobic
Polar
Positive
Negative
Special

πŸ’Š FDA-Approved ADC Drugs Using Non-Natural Linkers

2024
Trastuzumab Deruxtecan
HER2+ breast cancer, uses topoisomerase inhibitor payload
ADC
2022
Tisotumab Vedotin
Cervical cancer, monomethyl auristatin E payload
ADC
2021
Loncastuximab Tesirine
Diffuse large B-cell lymphoma
ADC
2019
Enfortumab Vedotin
Bladder cancer, Nectin-4 targeting
ADC
2017
Inotuzumab Ozogamicin
Acute lymphoblastic leukemia
ADC
2011
Brentuximab Vedotin
Hodgkin lymphoma, CD30 targeting
ADC
πŸ†

Achievement!

You designed your first protein